We are live on ! Find out more
CTXR icon

Citius Pharmaceuticals
CTXR

39 hedge funds and large institutions have $1.34M invested in Citius Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 4

73% more capital invested

Capital invested by funds: $773K → $1.34M (+$564K)

33% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 6

15% more funds holding

Funds holding: 34 → 39 (+5)

4.62% more ownership

Funds ownership: 3.67% → 8.29% (+4.6%)

Holders
39
Holders Change
+5
Holders Change %
+14.71%
% of All Funds
0.47%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
8
Reduced
6
Closed
4
Calls
$105K
Puts
–
Net Calls
+$105K
Net Calls Change
-$24K

Top Buyers

Rank Fund Capital Flow
1
HCM
Heights Capital Management
California
+$1M
2
XT
XTX Topco
Cayman Islands
+$114K
3
UBS Group
UBS Group
Switzerland
+$63.2K
4
Two Sigma Investments
Two Sigma Investments
New York
+$48.8K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$41.1K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$44.1K
2
NA
NewEdge Advisors
Louisiana
-$31.3K
3
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
-$12K
4
Simplex Trading
Simplex Trading
Illinois
-$11K
5
Jane Street
Jane Street
New York
-$1.16K
Name Holding Trade Value Shares
Change 		Change in
Stake
LC
26
Luminist Capital
Michigan
$338 – – –
NA
27
NewEdge Advisors
Louisiana
$311 -$31.3K -25,000 -98%
Bank of America
28
Bank of America
North Carolina
$238 -$144 -115 -27%
MMCM
29
Murphy & Mullick Capital Management
New York
$124 – – –
PGAM
30
Princeton Global Asset Management
New Jersey
$124 – – –
JP Morgan Chase
31
JP Morgan Chase
New York
$93 – – –
SWIM
32
Smallwood Wealth Investment Management
New Jersey
$93 – – –
BNP Paribas Financial Markets
33
BNP Paribas Financial Markets
France
$83 – – –
AAP
34
Arax Advisory Partners
Colorado
$65 – – –
FDCDDQ
35
Federation des caisses Desjardins du Quebec
Quebec, Canada
$61 – – –
HI
36
Harbour Investments
Wisconsin
$39 +$63 +50 New
FC
37
Fairscale Capital
New Hampshire
$33 – – –
Wells Fargo
38
Wells Fargo
California
$31 – – –
TWC
39
TD Waterhouse Canada
Ontario, Canada
$3 +$5 +4 New
Cambridge Investment Research Advisors
40
Cambridge Investment Research Advisors
Iowa
– -$12K -10,044 Closed
Simplex Trading
41
Simplex Trading
Illinois
– -$11K -9,556 Closed
LWMI
42
Legacy Wealth Management (Idaho)
Idaho
– -$1.15K -930 Closed
FFA
43
Farther Finance Advisors
California
– -$425 -343 Closed
1
2

CTXR Hedge Fund Activity: Q4 2025 in Review

39 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q4 2025, worth a combined $1.34M — up 73% from $773K a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new CTXR positions and 4 closed out — a net gain of 5 holders — while 8 added to existing stakes and 6 trimmed.

The largest buyer was Heights Capital Management, opening a new position worth an estimated $1M. The largest seller was Susquehanna International Group, cutting an estimated $44.1K.

  • 39 institutional investors held Citius Pharmaceuticals (CTXR) as of Q4 2025, up from 34 in Q3 2025.
  • Funds reported $1.34M of Citius Pharmaceuticals stock for Q4 2025, up 73% quarter-over-quarter.
  • 9 funds opened new Citius Pharmaceuticals positions in Q4 2025 and 4 closed out, a net change of +5 holders.
  • The largest Citius Pharmaceuticals buyer in Q4 2025 was Heights Capital Management, an estimated $1M added.
  • The largest Citius Pharmaceuticals seller in Q4 2025 was Susquehanna International Group, an estimated $44.1K sold.

Based on aggregated 13F filings for Q4 2025.